Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis

dc.contributor.authorSosa Díaz, Lilian Elisa
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorSilva Abreu, Marcelle
dc.contributor.authorEspinoza, Lupe Carolina
dc.contributor.authorRincón, María
dc.contributor.authorBozal de Febrer, Núria
dc.contributor.authorDomènech Cabrera, Òscar
dc.contributor.authorRodríguez Lagunas, María José
dc.contributor.authorClares Naveros, Beatriz
dc.date.accessioned2020-05-06T20:50:53Z
dc.date.available2020-05-06T20:50:53Z
dc.date.issued2019-07-03
dc.date.updated2020-05-06T20:50:53Z
dc.description.abstractThe present study was designed to develop a thermoreversible gel of Pluronic (P407) loaded amphotericin B (AmB-gel) for the dermal and vaginal treatment of candidiasis. P407 was used as a copolymer to exploit potential advantages related to increasing drug concentration in the tissue layer in order to provide a local effect. Parameters including internal structure, swelling, porosity, and short-term stability were determined. In addition, drug release profile and ex vivo skin and vaginal permeation studies were carried out. Antifungal efficacy was evaluated against strains of Candida spp. and atomic force microscopy (AFM) supported the results. The tolerance of AmB-gel was studied by evaluating biomechanical properties of skin and determining the irritation level in scarified rabbit skin supported by histological analysis. Results confirmed the development of a thermoreversible AmB-gel with high porosity exhibiting Newtonian behavior at 4 °C and pseudoplasticity at 32 °C as well as optimal stability for at least 90 days. The Amb-gel provided a sustained drug release following a Boltzmann sigmoidal model. Non permeation was observed in skin and vaginal mucosa, showing a high retained amount of AmB of 960.0 and 737.3 µg/g/cm2, respectively. In vitro antifungal efficacy showed that AmB-gel was more effective than Free-AmB in inhibiting strains of Candida spp. and these results were corroborated by AFM. Finally, tolerance studies showed that its application did not induce skin irritation nor alter its biophysical properties. Together, these results confirmed that AmB-gel could be proposed as a promising candidate for the clinical status in the treatment of skin and vaginal candidiasis.
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec691101
dc.identifier.issn1999-4923
dc.identifier.pmid31277267
dc.identifier.urihttps://hdl.handle.net/2445/158997
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11070312
dc.relation.ispartofPharmaceutics, 2019, vol. 11, num. 7, p. 312
dc.relation.urihttps://doi.org/10.3390/pharmaceutics11070312
dc.rightscc-by (c) Sosa Díaz, Lilian Elisa et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationCandidiasi
dc.subject.classificationCopolímers
dc.subject.classificationGels (Farmàcia)
dc.subject.otherCandidiasis
dc.subject.otherCopolymers
dc.subject.otherGels (Pharmacy)
dc.titleThermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
691101.pdf
Mida:
5.05 MB
Format:
Adobe Portable Document Format